Zeskind Benjamin J.'s Form 4 filing
Immuneering Corp (IMRX) · filed Mar 19, 2024
- Accession no.
- 0001790340-24-000026
- Filed
- Mar 19, 2024
- Trade date
- Mar 19, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $55.4K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zeskind Benjamin J.CIK 0001870062 | Director, Officer (PRESIDENT AND CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 19, 2024 | Class A Common Stock | PPurchaseAcquired | +20,000 | $2.77F1 | +$55,400 | 2,281,852 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.54 to $2.95. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
Referenced by the price of 1 transaction in Table I.